Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock.

Several other analysts have also recently weighed in on GANX. Oppenheimer reaffirmed an outperform rating and issued a $9.00 target price on shares of Gain Therapeutics in a report on Tuesday, April 23rd. Chardan Capital restated a buy rating and set a $6.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, March 27th.

Gain Therapeutics Stock Down 1.3 %

Shares of NASDAQ:GANX opened at $3.03 on Thursday. The firm’s 50 day moving average price is $3.97 and its 200 day moving average price is $3.44. The stock has a market cap of $49.15 million, a price-to-earnings ratio of -1.77 and a beta of 0.43. Gain Therapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $5.65. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Tuesday, March 26th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. As a group, equities research analysts predict that Gain Therapeutics will post -1.22 earnings per share for the current fiscal year.

Insider Activity at Gain Therapeutics

In other news, Director Jeffrey Scott Riley purchased 30,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were bought at an average price of $3.86 per share, with a total value of $115,800.00. Following the completion of the transaction, the director now directly owns 30,000 shares in the company, valued at approximately $115,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.00% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.